BRAF and melanoma: Genetic and pharmacological studies have shown that disruption of the BRAF-MEK-ERK pathway blocks the growth of melanoma cells harboring an oncogenic BRAF mutation and thus represents an attractive therapeutic target (Wellbrock et al., 2004; Miller and Mihm, 2006; Tsao et al., 2012).